News about "Wegovy"

UK MHRA Approves Wegovy for Treatment of MASH in Adults with Liver Fibrosis

The UK's Medicines and Healthcare products Regulatory Agency has conditionally approved Novo Nordisk's Wegovy (semaglutide) for treating metabolic-associated steatohepatitis (MASH) in adults with moderate-to-advanced liver fibrosis, subject to ongoing confirmatory clinical data.

Wegovy | 06/07/2026 | By News Bureau

Wegovy Pill Prescriptions Surpass 3 Million as Novo Nordisk Presents New ADA 2026 Data

Novo Nordisk announced that Wegovy pill prescriptions have surpassed 3 million since launch, marking one of the largest US pharmaceutical launches by volume. Most prescriptions are from people new to GLP-1 therapy, expanding access to obesity treatment, while new clinical analyses are being presented at ADA 2026.

Wegovy | 10/06/2026 | By News Bureau |  170

Novo Nordisk Higher-Dose Wegovy Shows 28 Percent Weight Loss in Early Responders

Novo Nordisk reports new analyses showing higher-dose Wegovy helped early responders achieve up to 28 percent weight loss, highlighting its effectiveness for obesity treatment regardless of response speed.

Wegovy | 13/05/2026 | By News Bureau |  111

Eli Lilly's Foundayo and Lower-Dose Zepbound Maintain Weight Loss in Late-Phase Trials

Eli Lilly and Company reports late-stage trial data showing Foundayo and lower-dose Zepbound helped patients maintain significant long-term weight loss after switching from higher-dose incretin therapies.

Wegovy | 13/05/2026 | By News Bureau |  120

UK MHRA Approves Single-Dose 7.2mg Wegovy Injection for Obesity Treatment

The UK Medicines and Healthcare products Regulatory Agency has approved a single-dose 7.2mg Wegovy pen, simplifying weekly treatment for adults with obesity and a BMI of 30 or higher.

Wegovy | 15/04/2026 | By News Bureau |  159

Vanda Pharmaceuticals Launches Thetis Study to Test NEREUS for GLP-1 Agonist-Induced Vomiting

Vanda Pharmaceuticals launches Thetis study, a multicenter clinical trial testing NEREUS (oral tradipitant) to prevent vomiting in patients starting high-dose GLP-1 receptor agonists, evaluating safety and efficacy.

Wegovy | 09/04/2026 | By News Bureau |  196

NICE Recommends Weekly Semaglutide Injection to Prevent Heart Attacks and Strokes

NICE advises use of semaglutide injections for patients with prior cardiovascular conditions and excess weight to lower risk of future serious events.

Wegovy | 04/04/2026 | By News Bureau |  114

UK MHRA Approves up to 7.2 mg Dose of Semaglutide for Obesity Treatment

The UK MHRA has approved a higher dose of semaglutide of up to 7.2 mg for weight management in adult patients with obesity. The regimen involves three 2.4 mg injections and is indicated for use alongside a reduced-calorie diet and increased physical activity in adults with a Body Mass Index (BMI) of 30 kg/m² or higher.

Wegovy | 17/01/2026 | By News Bureau |  157

Innovation Led Growth Dominates Indian Pharma Market in 2025

The India’s pharmaceutical market grew 10.6 percent year-on-year in December 2025, driven by chronic therapies, GLP-1 drugs, and strong innovation-led demand.

Wegovy | 15/01/2026 | By News Bureau |  1189

US FDA Approves Wegovy by Novo Nordisk as first Oral GLP-1 for Weight Loss

Wegovy’s approval is supported by phase III OASIS 4 trial data showing a mean weight loss of 16.6 percent, with the oral GLP-1 indicated for long-term weight management and reduction of major adverse cardiovascular events, and Novo Nordisk planning a US launch in early January 2026.

Wegovy | 23/12/2025 | By News Bureau |  325